Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy
Mukul Sharma, Eric E Smith, Lesly A Pearce, Kanjana S Perera, Scott E Kasner, Byung-Woo Yoon, Sebastian F Ameriso, Josep Puig, Dorte Damgaard, Jochen B Fiebach, Keith W Muir, Roland C Veltkamp, Danilo S Toni, Nikolay Shamalov, Rubens J Gagliardi, Robert Mikulik, Stefan T Engelter, Daniel Bereczki, Martin J O'Donnell, Feryal Saad, Ashkan Shoamanesh, Scott D Berkowitz, Hardi Mundl, Robert G Hart, NAVIGATE ESUS MRI Substudy Investigators, Mukul Sharma, Eric E Smith, Lesly A Pearce, Kanjana S Perera, Scott E Kasner, Byung-Woo Yoon, Sebastian F Ameriso, Josep Puig, Dorte Damgaard, Jochen B Fiebach, Keith W Muir, Roland C Veltkamp, Danilo S Toni, Nikolay Shamalov, Rubens J Gagliardi, Robert Mikulik, Stefan T Engelter, Daniel Bereczki, Martin J O'Donnell, Feryal Saad, Ashkan Shoamanesh, Scott D Berkowitz, Hardi Mundl, Robert G Hart, NAVIGATE ESUS MRI Substudy Investigators
Abstract
Background: Covert brain infarcts are associated with important neurological morbidity. Their incidence in patients with embolic stroke of undetermined source (ESUS) is unknown.
Aims: To assess the incidence of covert brain infarcts and cerebral microbleeds using MRI in a prospective substudy of the NAVIGATE ESUS randomized trial and to evaluate the effects of antithrombotic therapies.
Methods: At 87 sites in 15 countries, substudy participants were randomly assigned to receive rivaroxaban 15 mg daily or aspirin 100 mg daily and underwent brain MRI near randomization and after study termination. The primary outcome was incident brain infarct (clinical ischemic stroke or covert brain infarct). Brain infarcts and microbleeds were ascertained centrally by readers unaware of treatment. Treatment effects were estimated using logistic regression.
Results: Among the 718 substudy participants with interpretable, paired MRIs, the mean age was 67 years and 61% were men with a median of 52 days between the qualifying ischemic stroke and randomization and a median of seven days between randomization and baseline MRI. During the median (IQR) 11 (12) month interval between scans, clinical ischemic strokes occurred in 27 (4%) participants, while 60 (9%) of the remaining participants had an incident covert brain infarct detected by MRI. Assignment to rivaroxaban was not associated with reduction in the incidence of brain infarct (OR 0.77, 95% CI 0.49, 1.2) or of covert brain infarct among those without clinical stroke (OR 0.85, 95% CI 0.50, 1.4). New microbleeds were observed in 7% and did not differ among those assigned rivaroxaban vs. aspirin (HR 0.95, 95% CI 0.52-1.7).
Conclusions: Incident covert brain infarcts occurred in twice as many ESUS patients as a clinical ischemic stroke. Treatment with rivaroxaban compared with aspirin did not significantly reduce the incidence of covert brain infarcts or increase the incidence of microbleeds, but the confidence intervals for treatment effects were wide.Registration: https://www.clinicaltrials.gov. Unique identifier: NCT02313909.
Keywords: Anticoagulation; ESUS; cerebral microbleeds; covert stroke; embolic stroke; randomized clinical trial; rivaroxaban.
Conflict of interest statement
Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All co-authors or their institutions received payments from Bayer AG for participation in the NAVIGATE ESUS trial except for HM and SDB who are employed by Bayer AG.
Figures
References
- Smith EE, Saposnik G, Biessels GJ, et al. Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2017; 48: e44–e71.
- Vermeer SE, Longstreth WT, Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol 2007; 6: 611–619.
- Hart RG, Diener HC, Coutts SB, et al. on behalf of the Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13: 429–438.
- Hart RG, Sharma M, Mundl H, et al. for the NAVIGATE ESUS Steering Committee. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: design of the NAVIGATE ESUS randomized trial. Euro Stroke J 2016; 1: 146–154.
- Hart RG, Sharma M, Mundl H, for the NAVIGATE ESUS, Investigators. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 378: 2191–2201.
- Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822–838.
- Sharma M, Hart RG, Smith EE, et al. Rivaroxaban for prevention of covert brain infarcts and cognitive decline. Stroke 2020; 51: 2901–2909.
- Butcher K, Ng K, Sheridan P, et al. Dabigatran treatment of acute non-cardioembolic ischemic stroke. Stroke 2020; 51: 1190–1198.
- Sondergaard L, Kasner SE, Rhodes JF, for the Gore REDUCE Clinical Study Investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017; 377: 1033–1042.
- Pinter D, Gattringer T, Enzinger C, et al. Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. J Cerebral Blood Flow Met 2019; 39: 1669–1677.
- Hilal S, Baaij LGA, de Groot M, et al. Prevalence and clinical relevance of diffusion weighted imaging lesions. Neurol 2019; 93: e1058–e1067.
- O’Donnell MJ, Eikelboom JW, Yusuf S, et al. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. Am Heart J 2016; 178: 145–150.
Source: PubMed